Apollo Stack, MD
Pain Medicine · Omaha, NENPI 1962993261
Payments from drug & device makers
What this record shows
This record is dominated by grants: $5,000 of the $8,228 with a category attached, or 60.8%. Medtronic accounts for 78.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $6,393 and has fallen 81.4% since, to $1,189 in 2025.
Across 41 payments — averaging $200.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$850
- Nevro Corp.$389
- Boston Scientific$274
- Si-bone, Inc.$177
- SPR Therapeutics, Inc$47
- plus $16 from 1 others
What the payments were for
- Grants$5,00061%
- Travel & lodging$1,78322%
- Food & beverage$1,44518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 16 | $6,475 |
| Abbott | 8 | $850 |
| Nevro Corp. | 4 | $389 |
| Boston Scientific | 9 | $274 |
| Si-bone, Inc. | 2 | $177 |
| SPR Therapeutics, Inc | 1 | $47 |
| Vertex | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$5,000
- KYPHON EXPRESS II KYPHOPAK TRAY$878
- PROCLAIM$614
- INTELLIS ADAPTIVESTIM$297
- Senza$277
- Intracept$138
How this compares
$8,228 in reported general payments places this provider in the 65th percentile of 31 pain medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 84 | $2,504 |
| Pregabalin | 87 | $1,589 |
| Duloxetine Hcl | 96 | $679 |
| Gabapentin | 30 | $455 |
| Prednisone | 46 | $190 |
| Tizanidine Hcl | 18 | $144 |
| Meloxicam | 56 | $78 |
| Tramadol Hcl | 16 | $51 |
| Alprazolam | 15 | $22 |
| Diazepam | 20 | $20 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Omaha
- Matthew StottleOmaha$14K
- Katie BerkyOmaha$12K
- Tyrus SoaresOmaha$8K
- Jess RolandOmaha$8K
- Marshall LaddOmaha$7K
- James DevneyOmaha$5K
- Peter PiperisOmaha$4K
- Dan NichollsOmaha$3K
- Ernesto PadronOmaha$3K
- Christopher CriscuoloOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.